Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Soft Tissue Sarcoma
100%
Connective Tissue Cancer
75%
Progression Free Survival
57%
Arm
55%
Overall Survival
50%
Placebo
44%
Ripretinib
43%
Gastrointestinal Stromal Tumor
42%
Regorafenib
40%
Adverse Event
39%
Desmoid Tumor
36%
Diseases
35%
Leiomyosarcoma
30%
Neoplasm
26%
Ewing Sarcoma
26%
Synovial Sarcoma
25%
Tumor
24%
Imatinib
23%
Chordoma
23%
Dedifferentiated Liposarcoma
23%
Chemotherapy
21%
Quality of Life
21%
Osteosarcoma
20%
Malignant Neoplasm
20%
Intention-to-Treat Analysis
18%
Doxorubicin
18%
Clinical Trial
16%
Liposarcoma
16%
Pembrolizumab
15%
Patient-Reported Outcome
15%
Sunitinib
15%
Pazopanib
15%
Disease Exacerbation
14%
Angiosarcoma
14%
Liposarcoma Cell
14%
Retroperitoneal Sarcoma
14%
Nirogacestat
14%
Temozolomide
14%
Evofosfamide
14%
Selinexor
14%
Long-Term Outcome
14%
Oncology
13%
Tyrosine-Kinase Inhibitor
13%
Radiation Therapy
12%
Angioleiomyoma
12%
Esophagus
10%
Disease Free Survival
10%
Hazard Ratio
10%
Targeted Therapy
9%
Endoscopic Ultrasound
9%
Keyphrases
Phase II Trial
59%
Soft Tissue Sarcoma
57%
Sarcoma
50%
Ripretinib
50%
Overall Survival
46%
Imatinib
39%
Progression-free Survival
38%
Sunitinib
37%
Phase I Study
37%
Regorafenib
34%
Advanced Gastrointestinal Stromal Tumor
32%
Metastatic Soft Tissue Sarcoma
31%
Leiomyosarcoma
31%
Desmoid Tumor
28%
Angiosarcoma
28%
Dedifferentiated Liposarcoma (DDLPS)
27%
Placebo
27%
Tumor
26%
Ewing Sarcoma
26%
Gastrointestinal Stromal Tumor
24%
Pembrolizumab
23%
Pazopanib
22%
Gemcitabine
21%
Docetaxel
21%
Invictus
21%
Objective Response Rate
21%
Adverse Events
20%
Median Progression-free Survival
19%
Clinical Activity
19%
95% Confidence Interval
19%
Bone Sarcoma
16%
Advanced Soft Tissue Sarcoma
16%
Advanced Chordoma
16%
Chemotherapy
16%
Median Overall Survival
16%
Radiation Therapy
15%
Synovial Sarcoma
15%
Doxorubicin
15%
Partial Response
15%
Treatment Refractory
14%
Control Phase
14%
Temozolomide
14%
Randomized Clinical Trial
14%
Nirogacestat
14%
Dacarbazine
14%
Olaratumab
14%
Evofosfamide
14%
Long-term Safety
14%
Retroperitoneal Sarcoma
14%
Brachyury
14%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
59%
Ripretinib
57%
Soft Tissue Sarcoma
56%
Gastrointestinal Stromal Tumor
51%
Overall Survival
39%
Sunitinib
37%
Placebo
35%
Imatinib
32%
Adverse Event
29%
Pazopanib
29%
Gemcitabine
28%
Regorafenib
25%
Leiomyosarcoma
25%
Chemotherapy Regimens
21%
Clinical Trial
20%
Neoplasm
20%
Diseases
19%
Liposarcoma
19%
Connective Tissue Cancer
17%
Osteosarcoma
16%
Ewing Sarcoma
16%
Doxorubicin
15%
Solid Malignant Neoplasm
14%
Desmoid Tumor
14%
Docetaxel
14%
Prostate Cancer
14%
Olaratumab
14%
Evofosfamide
14%
Dacarbazine
14%
Chordoma
14%
Nirogacestat
14%
Protein Tyrosine Kinase Inhibitor
12%
Disease Exacerbation
12%
Synovial Sarcoma
11%
Pharmacokinetics
10%
Tolerability
10%
Ribonucleotide Reductase
9%
Biological Marker
9%
Phase II Trials
9%
Neutropenia
8%
Maximum Tolerated Dose
8%
Phase III Trials
8%
Dedifferentiated Liposarcoma
7%
Angiosarcoma
7%
Selinexor
7%
Carotuximab
7%
Metastatic Breast Cancer
7%
Infusion Related Reaction
7%
Sulindac Sulfone
7%
Secretase
7%